AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6422802 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural anaesthesia for 24 hours
Number of subjects: 18
Study 6422802 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 18
Study 6422802 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 18
Study 30365955 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (133 patients, 65%)
Number of subjects: 204
Study 30365955 — intervention group
Group type: COMPARATOR
Intervention: No surgical intervention (37 patients, 18%)
Number of subjects: 204
Study 30365955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resections (56 patients, 42%)
Number of subjects: 204
Study 30365955 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomies (60 patients, 45%)
Number of subjects: 204
Study 30365955 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonectomies (17 patients, 13%)
Number of subjects: 204
Study 29802800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 100
Study 29802800 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 100
Study 27343711 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA Soaked Gelfoam
Number of subjects: 90
Study 27343711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam
Number of subjects: 90
Study 27343711 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 25440809 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252)
Number of subjects: 504
Study 25440809 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment (control group, n = 252)
Number of subjects: 504
Study 25440809 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-treated patients
Number of subjects: 504
Study 25440809 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 504
Study 23157904 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage posterior correction and instrumentation without neurosurgery for syringomyelia.
Number of subjects: 19
Study 23157904 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgery (suboccipital decompression and syrinx shunting) followed by scoliosis correction.
Number of subjects: 19
Study 23157904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (study and control).
Number of subjects: 19
Study 20168272 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse diode laser
Number of subjects: 50
Study 20168272 — intervention group
Group type: COMPARATOR
Intervention: Modified Early Treatment Diabetic Retinopathy Study laser photocoagulation
Number of subjects: 50
Study 17413477 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐item Core Outcome Measure for whiplash (Core Whiplash Outcome Measure [CWOM])
Number of subjects: 481
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Up Bond F
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐Pop
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: optiBond solo Plus Self Etch
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NRC Nt
Number of subjects: 100
Study 15623999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop
Number of subjects: 100
Study 15623999 — intervention group
Group type: COMPARATOR
Intervention: Control bonding system (Prime & Bond NT) with phosphoric acid pre-etch
Number of subjects: 100
Study 12406532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (up to 2400 mg/day, titrated to 900 mg/day over 3 days, then increased as needed)
Number of subjects: 305
Study 12406532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 12406532 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 305
Study 10576366 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg bismuth subnitrate (BSN)
Number of subjects: 20
Study 10576366 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 mg colloidal bismuth subcitrate (CBS)
Number of subjects: 20
Study 8921139 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (MP)
Number of subjects: 178
Study 8921139 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (VCMP/VBAP)
Number of subjects: 178
Study 8921139 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients (70 years or more)
Number of subjects: 178
Study 1888630 — intervention group
Group type: EXPERIMENTAL
Intervention: C 50/HCTZ 25 once daily
Number of subjects: 199
Study 1888630 — intervention group
Group type: COMPARATOR
Intervention: C 25/HCTZ 12.5 twice daily
Number of subjects: 199
Study 6638418 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial double lumen tube for one-lung ventilation with intravenous anaesthesia and muscular relaxation
Number of subjects: 6
Study 6638418 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal intubation
Number of subjects: 6
Study 30136045 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF plus PEG‐IFN for 48 weeks (group A)
Number of subjects: 740
Study 30136045 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF plus PEG‐IFN for 16 weeks followed by TDF for 32 weeks (group B)
Number of subjects: 740
Study 30136045 — intervention group
Group type: COMPARATOR
Intervention: TDF for 120 weeks (group C)
Number of subjects: 740
Study 30136045 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN for 48 weeks (group D)
Number of subjects: 740
Study 28660669 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 103
Study 28660669 — intervention group
Group type: EXPERIMENTAL
Intervention: CBWT
Number of subjects: 103
Study 28660669 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 103
Study 26406150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 658
Study 26406150 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (10 mg daily)
Number of subjects: 658
Study 26406150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 658
Study 26406150 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 658
Study 23873901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with intravitreal ranibizumab and topical ketorolac (group 1)
Number of subjects: 56
Study 23873901 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab alone (group 2)
Number of subjects: 56
Study 19787290 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg)
Number of subjects: 36
Study 19787290 — intervention group
Group type: COMPARATOR
Intervention: standard therapy (control)
Number of subjects: 36
Study 19033682 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate (VS, 50 mg p.o. twice daily)
Number of subjects: 14
Study 19033682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16481737 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab (18.5 MBq/kg)
Number of subjects: 24
Study 16481737 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab (27.75 MBq/kg)
Number of subjects: 24
Study 16481737 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab (37 MBq/kg)
Number of subjects: 24
Study 16481737 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-labeled Metuximab
Number of subjects: 24
Study 15370932 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d) + Relapse Prevention therapy
Number of subjects: 80
Study 15370932 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (placebo) + Drug Counseling
Number of subjects: 80
Study 15370932 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including both NTX and placebo)
Number of subjects: 80
Study 15370932 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 80
Study 15370932 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication group (NTX)
Number of subjects: 80
Study 11092518 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy breakfast cereal (providing 36 g/d soy protein and 168 mg/d isoflavones)
Number of subjects: 25
Study 11092518 — intervention group
Group type: COMPARATOR
Intervention: Control breakfast cereal
Number of subjects: 25
Study 9327316 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 9327316 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study 8104730 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative platelet-rich plasma (PRP) 10 ml.kg-1
Number of subjects: 40
Study 8104730 — intervention group
Group type: COMPARATOR
Intervention: Control group without plateletpheresis
Number of subjects: 40
Study 3082694 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray plus terfenadine tablets (50 mcg flunisolide to each nostril twice daily and 60 mg terfenadine twice daily)
Number of subjects: 99
Study 3082694 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine alone (60 mg terfenadine twice daily)
Number of subjects: 99
Study 3272745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25% epidural, 6 to 12 ml/hour)
Number of subjects: 24
Study 3272745 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.1 mg/kg intramuscularly, no more frequently than every 4 hours)
Number of subjects: 24
Study 3272745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 24
Study 3272745 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 24
Study 29374796 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline subfoveal choroidal thickness (SCT)
Number of subjects: 60
Study 29374796 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SCT ≤124 μm
Number of subjects: 60
Study 29374796 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve (ROC) analysis
Number of subjects: 60
Study 27530775 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management web portal for COPD
Number of subjects: 0
Study 27530775 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of personal assistance integrated in existing care program
Number of subjects: 0
Study 26060503 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 50
Study 26060503 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 50
Study 23699530 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral sounds that preceded task-relevant visual targets (Experiment 1)
Number of subjects: 0
Study 23699530 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral sounds presented during purely auditory tasks (Experiments 2-4)
Number of subjects: 0
Study 23699530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden, intrusive sounds
Number of subjects: 0
Study 20506391 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg, 2 subcutaneous injections at 7-day intervals)
Number of subjects: 61
Study 20506391 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 61
Study 20506391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 18402744 — intervention group
Group type: EXPERIMENTAL
Intervention: KS pistol grip (26173 KC)
Number of subjects: 6
Study 18402744 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethicon driver (E 705R)
Number of subjects: 6
Study 18402744 — intervention group
Group type: EXPERIMENTAL
Intervention: KS finger grip (26167 SK)
Number of subjects: 6
Study 18402744 — intervention group
Group type: COMPARATOR
Intervention: KS palm grip (26173 ML)
Number of subjects: 6
Study 16368471 — intervention group
Group type: EXPERIMENTAL
Intervention: S21400 150 microg per day
Number of subjects: 335
Study 16368471 — intervention group
Group type: EXPERIMENTAL
Intervention: S21400 300 microg per day
Number of subjects: 335
Study 16368471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 15042530 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0
Study 15042530 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 11393212 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical bar soap
Number of subjects: 25
Study 11393212 — intervention group
Group type: COMPARATOR
Intervention: Syndet cleansing bar
Number of subjects: 25
Study 11393212 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap chamber test with classical bar soap
Number of subjects: 25
Study 11393212 — intervention group
Group type: COMPARATOR
Intervention: Soap chamber test with syndet bar
Number of subjects: 25
Study 11393212 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioengineering measurements with classical bar soap
Number of subjects: 25
Study 11393212 — intervention group
Group type: COMPARATOR
Intervention: Bioengineering measurements with syndet bar
Number of subjects: 25
Study 9059137 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone at 2.00 am (5 or 7.5 mg daily)
Number of subjects: 26
Study 9059137 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone at 7.30 am (5 or 7.5 mg daily)
Number of subjects: 26
Study 8365303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Inverse Ratio Ventilation (PC-IRV)
Number of subjects: 10
Study 8365303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 10
Study 8365303 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 10
Study 2874527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine (somatostatin-depleting agent) at maximum tolerated dosage for 2 weeks
Number of subjects: 5
Study 2874527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine (somatostatin-depleting agent)
Number of subjects: 5
Study 29982534 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructans (6 g/d)
Number of subjects: 270
Study 29982534 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control)
Number of subjects: 270
Study 24876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical approach using DISST family tests
Number of subjects: 71
Study 22415123 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐adherent silicone border foam dressing
Number of subjects: 100
Study 22415123 — intervention group
Group type: COMPARATOR
Intervention: Standard preventive care
Number of subjects: 100
Study 20361906 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-controlled ERP performed by experienced behavior therapists
Number of subjects: 118
Study 20361906 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-controlled ERP performed by master's students of clinical psychology
Number of subjects: 118
Study 20361906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled ERP performed by experienced behavior therapists
Number of subjects: 118
Study 20361906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled ERP performed by master's students of clinical psychology
Number of subjects: 118
Study 20361906 — intervention group
Group type: EXPERIMENTAL
Intervention: All modes of delivery of ERP
Number of subjects: 118
Study 19298037 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted technique
Number of subjects: 44
Study 19298037 — intervention group
Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 44
Study 15804155 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled temperature measurement system
Number of subjects: 17
Study 15804155 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI 500 arterial temperature sensor
Number of subjects: 17
Study 15804155 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased flow through the CDI sensor to approximately 400 mL/min
Number of subjects: 17
Study 12424162 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg per day for 14 days)
Number of subjects: 8070
Study 10836664 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride vaginal capsule
Number of subjects: 89
Study 10836664 — intervention group
Group type: COMPARATOR
Intervention: Benzalkonium chloride pessary
Number of subjects: 89
Study 9054781 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment alone
Number of subjects: 85
Study 9054781 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment with community workers
Number of subjects: 85
Study 9054781 — intervention group
Group type: COMPARATOR
Intervention: Brokered case management
Number of subjects: 85
Study 8409317 — intervention group
Group type: EXPERIMENTAL
Intervention: GoLYTELY followed by three Dulcolax capsules
Number of subjects: 160
Study 8409317 — intervention group
Group type: COMPARATOR
Intervention: GoLYTELY followed by three placebo capsules
Number of subjects: 160
Study 3096063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular nicomorphine
Number of subjects: 24
Study 3096063 — intervention group
Group type: COMPARATOR
Intervention: High thoracic epidural nicomorphine
Number of subjects: 24
Study 30686734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active finger movements or passive finger displacements during tactile stimulation
Number of subjects: 0
Study 30686734 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous tactile stimulation at randomized locations
Number of subjects: 0
Study 30686734 — intervention group
Group type: EXPERIMENTAL
Intervention: Two successive keypresses by different fingers at distinct locations
Number of subjects: 0
Study 30686734 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand movement placed far from the tactile stimulation site
Number of subjects: 0
Study 30686734 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal synchrony within 600 ms between movement and tactile stimulations
Number of subjects: 0
Study 29048187 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nicotine concentration of 36 mg/ml
Number of subjects: 64
Study 29048187 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid nicotine concentration of 0, 8, 18, or 36 mg/ml
Number of subjects: 64
Study 29048187 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG use
Number of subjects: 64
Study 29048187 — intervention group
Group type: EXPERIMENTAL
Intervention: Puff duration
Number of subjects: 64
Study 24828225 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional MRI
Number of subjects: 244
Study 24828225 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor histology
Number of subjects: 244
Study 24828225 — intervention group
Group type: COMPARATOR
Intervention: MRI and histology
Number of subjects: 244
Study 24828225 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 244
Study 23568034 — intervention group
Group type: COMPARATOR
Intervention: Virtual Chinese abacus
Number of subjects: 60
Study 23568034 — intervention group
Group type: EXPERIMENTAL
Intervention: Wooden Chinese abacus
Number of subjects: 60
Study 21712497 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg nilotinib as two 200-mg intact capsules
Number of subjects: 48
Study 21712497 — intervention group
Group type: EXPERIMENTAL
Intervention: nilotinib dispersed in 1 teaspoon of nonfat plain yogurt
Number of subjects: 48
Study 21712497 — intervention group
Group type: EXPERIMENTAL
Intervention: nilotinib dispersed in 1 teaspoon of applesauce
Number of subjects: 48
Study 19291387 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 49
Study 19291387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16432825 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (flush ligation of sites of reflux, stripping of the long saphenous vein and multiple phlebectomies)
Number of subjects: 246
Study 16432825 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (lifestyle advice)
Number of subjects: 246
Study 15319699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 45
Study 15319699 — intervention group
Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 45
Study 10899490 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/d)
Number of subjects: 60
Study 10899490 — intervention group
Group type: COMPARATOR
Intervention: Continuous combined HRT (ccHRT) containing estradiol (2 mg/d) + estriol (1 mg/d) + norethindrone acetate (1 mg/d)
Number of subjects: 60
Study 9035017 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 800 mg/day (400 mg bid)
Number of subjects: 3
Study 9035017 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg qid
Number of subjects: 3
Study 9035017 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg bid
Number of subjects: 3
Study 9035017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9035017 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 1000 mg/day
Number of subjects: 3
Study 9035017 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone 1500 mg/day
Number of subjects: 3
Study 7705193 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan (7.5 g/day for 3 months)
Number of subjects: 13
Study 7705193 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout period (2 months after discontinuation of Goshajinkigan)
Number of subjects: 13
Study 3588662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg bromocriptine
Number of subjects: 16
Study 3588662 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bromocriptine
Number of subjects: 16
Study 3588662 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bromocriptine
Number of subjects: 16
Study 3588662 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg imipramine
Number of subjects: 16
Study 3588662 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg imipramine
Number of subjects: 16